28 Jul Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases Posted at 10:00h in News Share ... Read More
31 Mar Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances Posted at 08:00h in News Share Read More
10 Mar Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets Posted at 15:00h in News Share Read More
07 Oct Complix receives €1.2 million VLAIO grant to develop a novel and differentiated class of anti-Covid-19 Alphabody™ therapeutics Posted at 07:00h in News Share Read More
14 Dec Complix receives €0.5 million grant to further develop its pipeline of proprietary Cell Penetrating Alphabodies™ against intracellular cancer targets Posted at 09:00h in News Share Read More
27 Jul Complix Announces Expanded Strategic Oncology Collaboration with MSD to Develop Cell-Penetrating Alphabodies Posted at 09:00h in News Share Read More
06 Jan Complix Enters into Strategic Collaboration with Merck Inc, worth up to US$ 280 million Posted at 09:00h in News Share Read More
14 Dec Complix Advances Novel Bispecific Immunotherapeutic CMX-02 – Enters Agreement with Selexis to Access SUREtechnology Platform™ Posted at 09:00h in News Share Read More
28 Oct Complix to Present at CHI’s 7th Annual PEGS Europe Summit, November 5, 2015 Posted at 09:00h in News Share Read More
